Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals, Inc., a prominent player in the ophthalmic pharmaceutical industry, is headquartered in the United States. Founded in 2008, the company has rapidly established itself as a leader in developing innovative therapies for eye diseases, particularly glaucoma and retinal disorders. Aerie's core products, including the unique eye drops Rhopressa® and Rocklatan®, are designed to lower intraocular pressure, setting them apart in a competitive market. With a strong focus on research and development, Aerie has achieved significant milestones, including successful product launches and expanding its operational footprint across North America and Europe. The company’s commitment to advancing eye care has positioned it favourably within the industry, earning recognition for its contributions to improving patient outcomes and enhancing the quality of life for those affected by vision-related conditions.
DitchCarbon Score
How does Aerie Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aerie Pharmaceuticals, Inc.'s score of 23 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aerie Pharmaceuticals, Inc.'s reported carbon emissions
Aerie Pharmaceuticals, Inc., headquartered in the US, currently does not have publicly available data regarding its carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined by the company. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and climate commitments, often setting ambitious targets to reduce their carbon footprint across Scope 1, 2, and 3 emissions. However, without specific data or commitments from Aerie Pharmaceuticals, it is unclear how they are addressing climate change or their carbon emissions. As the industry evolves, stakeholders may look for Aerie to establish clear climate strategies and reduction initiatives in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aerie Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
